- Home
- KDK vs ORIC Comparison
KDK vs ORIC Comparison
Compare KDK & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KDK
- ORIC
- Stock Information
- Founded
- KDK 2018
- ORIC 2014
- Country
- KDK United States
- ORIC United States
- Employees
- KDK N/A
- ORIC N/A
- Industry
- KDK EDP Services
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- KDK Technology
- ORIC Health Care
- Exchange
- KDK Nasdaq
- ORIC Nasdaq
- Market Cap
- KDK 1.3B
- ORIC 1.1B
- IPO Year
- KDK N/A
- ORIC 2020
- Fundamental
- Price
- KDK $6.28
- ORIC $11.58
- Analyst Decision
- KDK Strong Buy
- ORIC Strong Buy
- Analyst Count
- KDK 4
- ORIC 10
- Target Price
- KDK $15.63
- ORIC $18.00
- AVG Volume (30 Days)
- KDK 535.6K
- ORIC 1.1M
- Earning Date
- KDK 11-12-2025
- ORIC 11-13-2025
- Dividend Yield
- KDK N/A
- ORIC N/A
- EPS Growth
- KDK N/A
- ORIC N/A
- EPS
- KDK N/A
- ORIC N/A
- Revenue
- KDK $16,450,000.00
- ORIC N/A
- Revenue This Year
- KDK N/A
- ORIC N/A
- Revenue Next Year
- KDK N/A
- ORIC N/A
- P/E Ratio
- KDK N/A
- ORIC N/A
- Revenue Growth
- KDK N/A
- ORIC N/A
- 52 Week Low
- KDK $5.77
- ORIC $3.90
- 52 Week High
- KDK $11.62
- ORIC $14.93
- Technical
- Relative Strength Index (RSI)
- KDK N/A
- ORIC 40.11
- Support Level
- KDK N/A
- ORIC $11.28
- Resistance Level
- KDK N/A
- ORIC $13.45
- Average True Range (ATR)
- KDK 0.00
- ORIC 0.79
- MACD
- KDK 0.00
- ORIC -0.15
- Stochastic Oscillator
- KDK 0.00
- ORIC 13.10
About KDK Kodiak AI Inc. Common Stock
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.